APA (7th ed.) Citation

Sebastiaan J. W. vanKraaij, Pim Gal, Laura G. J. M. Borghans, Erica S. Klaassen, Francis Dijkstra, Christopher Winrow, . . . Geert Jan Groeneveld. (2023). First‐in‐human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator. Wiley.

Chicago Style (17th ed.) Citation

Sebastiaan J. W. vanKraaij, Pim Gal, Laura G. J. M. Borghans, Erica S. Klaassen, Francis Dijkstra, Christopher Winrow, Chad Glasser, and Geert Jan Groeneveld. First‐in‐human Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zagociguat (CY6463), a CNS‐penetrant Soluble Guanylyl Cyclase Stimulator. Wiley, 2023.

MLA (9th ed.) Citation

Sebastiaan J. W. vanKraaij, et al. First‐in‐human Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zagociguat (CY6463), a CNS‐penetrant Soluble Guanylyl Cyclase Stimulator. Wiley, 2023.